When a vaccine contains both PD-L1-silencing shRNA and IL-12, it can exhibit anti-melanoma activities, because PD-L1-silencing shRNA can increase the T cell numbers, and IL-12can inhibit tumor growth (81). The gene discussed is CD274; the disease is neoplasm.